Bioengineered Protein Drugs Market
Bioengineered Protein Drugs Market By Drug Type (Therapeutic Proteins, Monoclonal Antibodies, Vaccines), By Disease (Cancer, Diabetes, Autoimmune Disorder, Infectious Diseases, Haematopoiesis, CVD), By End User, By Region- Global Market Insights 2020 to 2025
Analysis of Bioengineered Protein Drugs market covering 30 + countries including analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
Bioengineered Protein Drugs Market Outlook
The quest for bioengineered protein drugs continues to surge among patients, as these are found to have relatively less side-effects and are more effective as compared to other drugs.
Sensing the growing demand for bioengineered protein drugs, market players are increasing their investments towards the development of a wide range of products that include therapeutic proteins, vaccines, and monoclonal antibodies.
The sales of therapeutic proteins are projected to offer highest value to the bioengineered protein drugs market, exceeding US$ 150 Bn by 2025. High adoption of these drugs is attributable to their competency to maintain the required protein levels in patients, and aid in the treatment of cancer, anaemia, hepatitis B/C, and haemophilia, among others.
Besides this, growing significance of preventive care in the healthcare sector is improving sales prospects for bioengineered protein drugs in vaccine formulations.
A recent report added to the comprehensive repository of Fact.MR highlights the adoption rate of vaccines, which is portended to witness a surge at a CAGR of 8.4% in the bioengineered protein drugs market during the forecast period (2020-2025).
Don't Need a Global Report?
save 40%! on Country & Region specific reports
Low Returns on High Investment – A Hindrance to Bioengineered Protein Drugs Market Growth
Rise in the number of FDA approvals for bioengineered protein drugs is encouraging market players to increase investments in research & development activities to diversify their product portfolio.
For instance, Eli Lilly and Company invests nearly 23% of its annual revenue, while Biogen spends around 22% of its revenue share, in the pharmaceutical sector. However, increasing penetration of biosimilar products and generic drugs filters out the sales potential of expensive branded bioengineered protein drugs.
Humira is a highly prescribed drug by doctors for the treatment of rheumatoid arthritis, Crohn's disease, ankylosing spondylitis, psoriatic arthritis, chronic plaque psoriasis, and polyarticular arthritis. However, the long-term consumption of this monoclonal antibody is highly unaffordable for most patients, as it lacks reimbursement coverage.
According to the AARP Public Policy Institute and the University of Minnesota’s PRIME Institute, the cost of 40 mg Humira injectable pens tripled from 2006 and 2017. Such an exponential increase in the prices of branded drugs is offering generic drugs the ground to thrive, and, in turn, limiting the RoI potential of leading players in the bioengineered protein drugs market.
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
High Cost of Branded Drugs Inadvertently Fuelling Growth of Asia Pacific Bioengineered Protein Drugs Market
High cost associated with branded drugs is hampering the growth of leading players, who are based in developed regions such as North America and Europe.
However, players operating in Asia Pacific are taking a cue and investing in the development of biosimilar and generic drugs that cost merely 20% of branded drugs. This is limiting the penetration of branded drugs in Asia Pacific and leading to a surge in the popularity of generic ones, which is increasing revenue potential of the bioengineered protein drugs market in this region.
According to the National Health Commission, over 2,000 people died of infectious diseases such as cholera and plague in China, in August 2019. Such an alarming death rate is encouraging the adoption of therapeutics, especially in densely populated countries such as China and India.
Also, a huge geriatric population base in Japan seeking cure for arthritis is further strengthening the position of Asia Pacific in the global bioengineered protein drugs market.
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
Bioengineered Protein Drugs Market – Assessment of Key Segments
Authors of this comprehensive study have classified the market into key segments for an in-depth study of the bioengineered protein drugs market. Categorisation of the bioengineered protein drugs market is based on drug type, disease, end user, and region.
This detailed study also offers information about the incremental opportunity present in the bioengineered protein drugs market during the forecast period. Key segments considered while studying the bioengineered protein drugs market include:
| Drug Type |
|
| Disease |
|
| End User |
|
| Region |
|
Revenue of the bioengineered protein drugs market has been evaluated in terms of US$ Mn for the period of 2020 to 2025. In addition to this, compound annual growth rate has been calculated for all key segments for the forecast period of 2020-2025, considering 2019 as the base year.
Table of Content
1 Preface 1.1 Market Definition and Scope 1.2 Market Segmentation 1.3 Key Research Objectives 1.4 Research Highlights 2 Assumptions and Research Methodology 3 Executive Summary: Global Bioengineered Protein Drugs Market 4 Market Overview 4.1 Introduction 4.1.1 Product Overview 4.1.2 Industry Evolution / Developments 4.1.3 Key Market Indicators 4.2 Market Dynamics 4.2.1 Drivers 4.2.2 Restraints 4.2.3 Opportunity 4.3 Market Revenue Projections 4.4 Porter’s Five Force Analysis 4.5 Value Chain Analysis 4.6 Market Outlook 5 Global Bioengineered Protein Drugs Market Analysis and Forecasts, by Drug Type 5.1 Key Findings / Developments 5.2 Introduction & Definition 5.3 Market Value Forecast by Drug Type, 2020–2025 5.3.1 Monoclonal Antibody 5.3.1.1 Humira 5.3.1.2 Rituxan 5.3.1.3 Avastin 5.3.1.4 Herceptin 5.3.1.5 Remicade 5.3.1.6 Lucentis 5.3.1.7 Enbrel 5.3.1.8 Synazis 5.3.1.9 others 5.3.2 Therapeutic Proteins Market By Type 5.3.2.1 Hormones 5.3.2.2 Cytokines 5.3.2.2.1 Neupogen 5.3.2.2.2 Neulasta 5.3.2.2.3 Interferon Alpha 5.3.2.2.4 Erythropoietin Alpha 5.3.2.2.5 Interleukin 5.3.2.2.6 Others 5.3.2.3 Blood Factor 5.3.2.4 Enzyme Therapy 5.3.2.4.1 Systemic Enzyme Therapy 5.3.2.4.2 Digestive Enzyme Therapy 5.3.2.5 Thrombolytics 5.3.2.5.1 tPA 5.3.2.5.2 Streptokinase 5.3.2.5.3 Urokinase 5.3.2.6 Vaccines 5.4 Key Trends 5.5 Market Attractiveness by Drug Type 6 Global Bioengineered Protein Drugs Market Analysis and Forecasts, by Disease 6.1 Key Findings / Developments 6.2 Introduction & Definition 6.3 Market Value Forecast by Disease, 2020–2025 6.3.1 Cancer 6.3.2 Diabetes 6.3.3 Autoimmune Disorder 6.3.4 Infectious Disease 6.3.5 Hematopoiesis 6.3.6 CVD 6.3.7 Neurodegenerative 6.3.8 Others 6.4 key Trends 6.5 Market Attractiveness by Disease 7 Global Bioengineered Protein Drugs Market Analysis and Forecasts, by End-user 7.1 Key Findings / Developments 7.2 Introduction & Definition 7.3 Market Value Forecast by End-user, 2020–2025 7.3.1 Pharma and Biotech Companies 7.3.2 CROs 7.3.3 Research Institutes 7.4 Key Trends 7.5 Market Attractiveness by End-user 8 Global Bioengineered Protein Drugs Market Analysis and Forecasts, by Region 8.1 Policies and Regulations 8.2 Market Value Forecast by Region 8.2.1 North America 8.2.2 Europe 8.2.3 Asia Pacific 8.2.4 Latin America 8.2.5 Middle East & Africa 8.3 Market Attractiveness by Region 9 North America Bioengineered Protein Drugs Market Analysis and Forecasts 9.1 Market Value Forecast by Country, 2020–2025 9.1.1 U.S. 9.1.2 Canada 9.2 Market Value Forecast by Drug Type, 2020–2025 9.3 Market Value Forecast by Disease, 2020–2025 9.4 Market Value Forecast by End - User, 2020–2025 9.5 Market Attractiveness Analysis 9.5.1 By Country 9.5.2 By Drug Type 9.5.3 By Disease 9.5.4 By End-user 10 Europe Bioengineered Protein Drugs Market Analysis and Forecasts 10.1 Market Value Forecast by Country, 2020–2025 10.1.1 Germany 10.1.2 Italy 10.1.3 France 10.1.4 U.K. 10.1.5 Spain 10.1.6 Rest of Europe 10.2 Market Value Forecast by Drug Type, 2020–2025 10.3 Market Value Forecast by Disease, 2020–2025 10.4 Market Value Forecast by End-user, 2020–2025 10.5 Market Attractiveness Analysis 10.5.1 By Country 10.5.2 By Drug Type 10.5.3 By Disease 10.5.4 By End-user 11 Asia Pacific Bioengineered Protein Drugs Market Analysis and Forecasts 11.1 Market Value Forecast by Country, 2020–2025 11.1.1 Japan 11.1.2 China 11.1.3 India 11.1.4 Rest of APAC 11.2 Market Value Forecast by Drug Type, 2020–2025 11.3 Market Value Forecast by Disease, 2020–2025 11.4 Market Value Forecast by End-user, 2020–2025 11.5 Market Attractiveness Analysis 11.5.1 By Country 11.5.2 By Drug Type 11.5.3 By Disease 11.5.4 By End-user 12 Latin America Bioengineered Protein Drugs Market Analysis and Forecasts 12.1 Market Value Forecast by Country, 2020–2025 12.1.1 Brazil 12.1.2 Mexico 12.1.3 Rest of LATAM 12.2 Market Value Forecast by Drug Type, 2020–2025 12.3 Market Value Forecast by Disease, 2020–2025 12.4 Market Value Forecast by End-user, 2020–2025 12.5 Market Attractiveness Analysis 12.5.1 By Country 12.5.2 By Drug Type 12.5.3 By Disease 12.5.4 By End-user 13 Middle East & Africa Bioengineered Protein Drugs Market Analysis and Forecasts 13.1 Market Value Forecast by Country, 2020–2025 13.1.1 South Africa 13.1.2 Saudi Arabia 13.1.3 Rest of MEA 13.2 Market Value Forecast by Drug Type, 2020–2025 13.3 Market Value Forecast by Disease, 2020–2025 13.4 Market Value Forecast by End-user, 2020–2025 13.5 Market Attractiveness Analysis 13.5.1 By Country 13.5.2 By Drug Type 13.5.3 By Disease 13.5.4 By End-user 14 Competitive Landscape 14.1 Market Share Analysis by Company 2019 14.2 Company Profiles 14.2.1 Abbott Laboratories 14.2.1.1 Company Details 14.2.1.2 Company Description 14.2.1.3 Business Overview 14.2.1.4 SWOT Analysis 14.2.1.5 Financial Analysis 14.2.1.6 Strategic Overview 14.2.2 Amgen Inc. 14.2.2.1 Company Details 14.2.2.2 Company Description 14.2.2.3 Business Overview 14.2.2.4 SWOT Analysis 14.2.2.5 Financial Analysis 14.2.2.6 Strategic Overview 14.2.3 Bayer AG 14.2.3.1 Company Details 14.2.3.2 Company Description 14.2.3.3 Business Overview 14.2.3.4 SWOT Analysis 14.2.3.5 Financial Analysis 14.2.3.6 Strategic Overview 14.2.4 Biocon Ltd. 14.2.4.1 Company Details 14.2.4.2 Company Description 14.2.4.3 Business Overview 14.2.4.4 SWOT Analysis 14.2.4.5 Financial Analysis 14.2.4.6 Strategic Overview 14.2.5 Dr. Reddy’s Laboratories 14.2.5.1 Company Details 14.2.5.2 Company Description 14.2.5.3 Business Overview 14.2.5.4 SWOT Analysis 14.2.5.5 Financial Analysis 14.2.5.6 Strategic Overview 14.2.6 Eli Lilly and Comapny 14.2.6.1 Company Details 14.2.6.2 Company Description 14.2.6.3 Business Overview 14.2.6.4 SWOT Analysis 14.2.6.5 Financial Analysis 14.2.6.6 Strategic Overview 14.2.7 F. Hoffmann – La Roche Ltd. 14.2.7.1 Company Details 14.2.7.2 Company Description 14.2.7.3 Business Overview 14.2.7.4 SWOT Analysis 14.2.7.5 Financial Analysis 14.2.7.6 Strategic Overview 14.2.8 Fresenius kabi 14.2.8.1 Company Details 14.2.8.2 Company Description 14.2.8.3 Business Overview 14.2.8.4 SWOT Analysis 14.2.8.5 Financial Analysis 14.2.8.6 Strategic Overview 14.2.9 GlaxoSmithKline plc 14.2.9.1 Company Details 14.2.9.2 Company Description 14.2.9.3 Business Overview 14.2.9.4 SWOT Analysis 14.2.9.5 Financial Analysis 14.2.9.6 Strategic Overview 14.2.10 Johnson & Johnson (Janseen) 14.2.10.1 Company Details 14.2.10.2 Company Description 14.2.10.3 Business Overview 14.2.10.4 SWOT Analysis 14.2.10.5 Financial Analysis 14.2.10.6 Strategic Overview 14.2.11 Merck & Co., Inc. 14.2.11.1 Company Details 14.2.11.2 Company Description 14.2.11.3 Business Overview 14.2.11.4 SWOT Analysis 14.2.11.5 Financial Analysis 14.2.11.6 Strategic Overview 14.2.12 Novartis AG 14.2.12.1 Company Details 14.2.12.2 Company Description 14.2.12.3 Business Overview 14.2.12.4 SWOT Analysis 14.2.12.5 Financial Analysis 14.2.12.6 Strategic Overview 14.2.13 Panacea Biotec 14.2.13.1 Company Details 14.2.13.2 Company Description 14.2.13.3 Business Overview 14.2.13.4 SWOT Analysis 14.2.13.5 Financial Analysis 14.2.13.6 Strategic Overview 14.2.14 ProBioGen AG 14.2.14.1 Company Details 14.2.14.2 Company Description 14.2.14.3 Business Overview 14.2.14.4 SWOT Analysis 14.2.14.5 Financial Analysis 14.2.14.6 Strategic Overview 14.2.15 Reliance Life Science Pvt. Ltd. 14.2.15.1 Company Details 14.2.15.2 Company Description 14.2.15.3 Business Overview 14.2.15.4 SWOT Analysis 14.2.15.5 Financial Analysis 14.2.15.6 Strategic Overview 14.2.16 Sanofi 14.2.16.1 Company Details 14.2.16.2 Company Description 14.2.16.3 Business Overview 14.2.16.4 SWOT Analysis 14.2.16.5 Financial Analysis 14.2.16.6 Strategic Overview
Don't Need a Global Report?
save 40%! on Country & Region specific reports
List Of Table
Table 1: Table 1: Global Bioengineered Proteins Drugs Market Size (US$ Mn) Forecast, by Drug Type, 2020–2025
Table 2: Global Monoclonal Antibodies Drugs Market Size (US$ Mn) Forecast, by Type, 2020–2025
Table 3: Global Therapeutic Proteins Drugs Market Size (US$ Mn) Forecast, by Type, 2020–2025
Table 4: Global Cytokines Drugs Market Size (US$ Mn) Forecast, by Type, 2020–2025
Table 5: Global Thrombolytics Drugs Market Size (US$ Mn) Forecast, by Type, 2020–2025
Table 6: Global Enzyme Therapy Market Size (US$ Mn) Forecast, by Type, 2020–2025
Table 7: Global Bioengineered Proteins Drugs Market Size (US$ Mn) Forecast, by Disease, 2020–2025
Table 8: Global Bioengineered Proteins Drugs Market Size (US$ Mn) Forecast, by End-users, 2020–2025
Table 9: Global Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, by Region, 2020–2025
Table 10: North America Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, by Country, 2020–2025
Table 11: North America Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, by Drug Type, 2020–2025
Table 12: North America Monoclonal Antibody Drugs Market Size (US$ Mn) Forecast, by Type, 2020–2025
Table 13: North America Therapeutic Protein Drugs Market Size (US$ Mn) Forecast, by Type, 2020–2025
Table 14: North America Cytokine Drugs Market Size (US$ Mn) Forecast, by Type, 2020–2025
Table 15: North America Thrombolytics Market Size (US$ Mn) Forecast, by Type, 2020–2025
Table 16: North America Enzyme Therapy Market Size (US$ Mn) Forecast, by Type, 2020–2025
Table 17: North America Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, by Disease, 2020–2025
Table 18: North America Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, by End-user, 2020–2025
Table 19: Europe Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, by Country, 2020–2025
Table 20: Europe Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, by Drug Type, 2020–2025
Table 21: Europe Monoclonal Antibody Drugs Market Size (US$ Mn) Forecast, by Type, 2020–2025
Table 22: Europe Therapeutic Protein Drugs Market Size (US$ Mn) Forecast, by Type, 2020–2025
Table 23: Europe Cytokines Drugs Market Size (US$ Mn) Forecast, by Type, 2020–2025
Table 24: Europe Thrombolytics Market Size (US$ Mn) Forecast, by Drug Type (Thrombolytics), 2020–2025
Table 25: Europe Enzyme Therapy Market Size (US$ Mn) Forecast, by Type, 2020–2025
Table 26: Europe Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, by Disease, 2020–2025
Table 27: Europe Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, by End-user, 2020–2025
Table 28: Asia Pacific Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, by Country, 2020–2025
Table 29: Asia Pacific Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, by Drug Type, 2020–2025
Table 30: Asia Pacific Monoclonal Antibody Market Size (US$ Mn) Forecast, by Type, 2020–2025
Table 31: Asia Pacific Therapeutic Proteins Drugs Market Size (US$ Mn) Forecast, by Type, 2020–2025
Table 32: Asia Pacific Cytokines Market Size (US$ Mn) Forecast, by Type, 2020–2025
Table 33: Asia Pacific Thrombolytics Market Size (US$ Mn) Forecast, by Type, 2020–2025
Table 34: Asia Pacific Enzyme Therapy Market Size (US$ Mn) Forecast, by Type, 2020–2025
Table 35: Asia Pacific Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, by Disease, 2020–2025
Table 36: Asia Pacific Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, by End-user, 2020–2025
Table 37: Latin America Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, by Country, 2020–2025
Table 38: Latin America Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, by Drug Type, 2020–2025
Table 39: Latin America Monoclonal Antibody Drugs Market Size (US$ Mn) Forecast, by Type, 2020–2025
Table 40: Latin America Therapeutic Protein Drugs Market Size (US$ Mn) Forecast, by Type, 2020–2025
Table 41: Latin America Cytokines Drugs Market Size (US$ Mn) Forecast, by Type, 2020–2025
Table 42: Latin America Thrombolytics Market Size (US$ Mn) Forecast, by Drug Type (Thrombolytics), 2020–2025
Table 43: Latin America Enzyme Therapy Market Size (US$ Mn) Forecast, by Type, 2020–2025
Table 44: Latin America Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, by Disease, 2020–2025
Table 45: Latin America Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, by End-user, 2020–2025
Table 46: MEA Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, by Country, 2020–2025
Table 47: MEA Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, by Drug Type, 2020–2025
Table 48: MEA Monoclonal Antibody Drugs Market Size (US$ Mn) Forecast, by Type, 2020–2025
Table 49: MEA Therapeutic Protein Drugs Market Size (US$ Mn) Forecast, by Type, 2020–2025
Table 50: MEA Cytokines Drugs Market Size (US$ Mn) Forecast, by Type, 2020–2025
Table 51: MEA Thrombolytics Market Size (US$ Mn) Forecast, by Drug Type (Thrombolytics), 2020–2025
Table 52: MEA Enzyme Therapy Market Size (US$ Mn) Forecast, by Type, 2020–2025
Table 53: MEA Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, by Disease, 2020–2025
Table 54: MEA Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, by End-user, 2020–2025
Table 55: India Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, by Drug Type, 2020–2025
Table 56: India Monoclonal Antibody Drugs Market Size (US$ Mn) Forecast, by Type, 2020–2025
Table 57: India Therapeutic Protein Drugs Market Size (US$ Mn) Forecast, by Type, 2020–2025
Table 58: India Cytokines Drugs Market Size (US$ Mn) Forecast, by Type, 2020–2025
Table 59: India Thrombolytics Market Size (US$ Mn) Forecast, by Drug Type (Thrombolytics), 2020–2025
Table 60: India Enzyme Therapy Market Size (US$ Mn) Forecast, by Type, 2020–2025
Table 61: India Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, by Disease, 2020–2025
Table 62: India Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, by End-user, 2020–2025
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
List Of Figures
Figure 1: Global Bioengineered Protein Drugs Market Size (US$ Mn) and Forecast, 2019–2024
Figure 2: Market Value Share, by Drug Type (2019)
Figure 3: Market Value Share, by Disease (2019)
Figure 4: Market Value Share, by End-User (2019)
Figure 5: Market Value Share, by Region (2019)
Figure 6: Global Bioengineered Proteins Drugs Market Value Share Analysis, by Drug Type, 2019 and 2025
Figure 7: Global Monoclonal Antibodies Drugs Market Value Share Analysis, by Type, 2019 and 2025
Figure 8: Global Therapeutic Proteins Drugs Market Value Share Analysis, by Type, 2019 and 2025
Figure 9: Global Cytokines Drugs Market Value Share Analysis, by Type, 2019 and 2025
Figure 10: Global Thrombolytics Drugs Market Value Share Analysis, by Type, 2019 and 2025
Figure 11: Global Enzyme Therapy Market Value Share Analysis, by Type, 2019 and 2025
Figure 12: Global Therapeutic Proteins Market Value (US$ Mn) and Y-o-Y Growth (%), 2020–2025
Figure 13: Global Monoclonal Antibodies Market Value (US$ Mn) and Y-o-Y Growth (%), 2020–2025
Figure 14: Global Vaccines Market Value (US$ Mn) and Y-o-Y Growth (%), 2020–2025
Figure 15: Global Bioengineered Proteins Drugs Market Attractiveness Analysis, by Drug Type
Figure 16: Global Bioengineered Proteins Drugs Market Value Share Analysis, by Disease, 2019 and 2025
Figure 17: Global Cancer Bioengineered Proteins Drugs Market Value (US$ Mn) and Y-o-Y Growth (%), 2020–2025
Figure 18: Global Diabetes Bioengineered Proteins Drugs Market Value (US$ Mn) and Y-o-Y Growth (%), 2020–2025
Figure 19: Global Infectious Disease Bioengineered Proteins Drugs Market Value (US$ Mn) and Y-o-Y Growth (%), 2020–2025
Figure 20: Global Autoimmune Disorders Bioengineered Proteins Drugs Market Value (US$ Mn) and Y-o-Y Growth (%), 2020–2025
Figure 21: Global Hematopoiesis Bioengineered Proteins Drugs Market Value (US$ Mn) and Y-o-Y Growth (%), 2020–2025
Figure 22: Global CVD Bioengineered Proteins Drugs Market Value (US$ Mn) and Y-o-Y Growth (%), 2020–2025
Figure 23: Global Neurodegenerative Disease Bioengineered Proteins Drugs Market Value (US$ Mn) and Y-o-Y Growth (%), 2020–2025
Figure 24: Global Others Bioengineered Proteins Drugs Market Value (US$ Mn) and Y-o-Y Growth (%), 2020–2025
Figure 25: Global Bioengineered Proteins Drugs Market Attractiveness Analysis, by Disease
Figure 26: Global Bioengineered Proteins Drugs Market Value Share Analysis, by End-users, 2019 and 2025
Figure 27: Global Pharmaceutical Companies and Biotechnological Companies Bioengineered Proteins Drugs Market Value (US$ Mn) and Y-o-Y Growth (%), 2020–2025
Figure 28: Global Contract Research Organizations Bioengineered Proteins Drugs Market Value (US$ Mn) and Y-o-Y Growth (%), 2017-2025
Figure 29: Global Research Institutes Bioengineered Proteins Drugs Market Value (US$ Mn) and Y-o-Y Growth (%), 2020–2025
Figure 30: Global Bioengineered Proteins Drugs Market Attractiveness Analysis, by End-users
Figure 31: North America Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, 2020–2025
Figure 32: Europe Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, 2020–2025
Figure 33: Asia Pacific Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, 2020–2025
Figure 34: Latin America Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, 2020–2025
Figure 35: MEA Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, 2020–2025
Figure 36: Global Bioengineered Protein Drugs Market Attractiveness Analysis, by Region
Figure 37: U.S. Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, 2020–2025
Figure 38: Canada Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, 2020–2025
Figure 39: North America Bioengineered Protein Drugs Market Attractiveness Analysis, by Country
Figure 40: North Bioengineered Protein Drugs Market Attractiveness Analysis, by Drug Type
Figure 41: North America Bioengineered Protein Drugs Market Attractiveness Analysis, by Disease
Figure 42: North America Bioengineered Protein Drugs Market Attractiveness Analysis, by End-user
Figure 43: Germany Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, 2020–2025
Figure 44: France Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, 2020–2025
Figure 45: U.K. Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, 2020–2025
Figure 46: Italy Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, 2020–2025
Figure 47: Spain Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, 2020–2025
Figure 48: Rest of Europe Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, 2020–2025
Figure 49: Europe Bioengineered Protein Drugs Market Attractiveness Analysis, by Country
Figure 50: Europe Bioengineered Protein Drugs Market Attractiveness Analysis, by Drug Types
Figure 51: Europe Bioengineered Protein Drugs Market Attractiveness Analysis, by Disease
Figure 52: Europe Bioengineered Protein Drugs Market Attractiveness Analysis, by End-user
Figure 53: China Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, 2020–2025
Figure 54: Japan Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, 2020–2025
Figure 55: India Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, 2020–2025
Figure 56: Australia Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, 2020–2025
Figure 57: Rest of APAC Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, 2020–2025
Figure 58: Asia Pacific Bioengineered Protein Drugs Market Attractiveness Analysis, by Country
Figure 59: Asia Pacific Bioengineered Protein Drugs Market Attractiveness Analysis, by Drug Types
Figure 60: Asia Pacific Bioengineered Protein Drugs Market Attractiveness Analysis, by Disease
Figure 61: Asia Pacific Bioengineered Protein Drugs Market Attractiveness Analysis, by End-user
Figure 62: Brazil Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, 2020–2025
Figure 63: Mexico Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, 2020–2025
Figure 64: Rest of LATAM Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, 2020–2025
Figure 65: Latin America Bioengineered Protein Drugs Market Attractiveness Analysis, by Country
Figure 66: Latin America Bioengineered Protein Drugs Market Attractiveness Analysis, by Drug Type
Figure 67: Latin America Bioengineered Protein Drugs Market Attractiveness Analysis, by Disease
Figure 68: Latin America Bioengineered Protein Drugs Market Attractiveness Analysis, by End-user
Figure 69: GCC Countries Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, 2020–2025
Figure 70: South Africa Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, 2020–2025
Figure 71: Rest of MEA Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, 2020–2025
Figure 72: MEA Bioengineered Protein Drugs Market Attractiveness Analysis, by Country
Figure 73: MEA Bioengineered Protein Drugs Market Attractiveness Analysis, by Drug Types
Figure 74: MEA Bioengineered Protein Drugs Market Attractiveness Analysis, by Disease
Figure 75: MEA Bioengineered Protein Drugs Market Attractiveness Analysis, by End-user
Figure 76: India Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, 2020–2025
Figure 77: India Bioengineered Protein Drugs Market Attractiveness Analysis, by Drug Type
Figure 78: India Bioengineered Protein Drugs Market Attractiveness Analysis, by Disease
Figure 79: India Bioengineered Protein Drugs Market Attractiveness Analysis, by End-users
Figure 80: Monoclonal Antibodies Bioengineered Protein Therapeutics Market Share Analysis By Company (2019)
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
- FAQs -
How much is the sales of therapeutic proteins are projected to offer by2025?
The sales of therapeutic proteins are projected to offer highest value to the bioengineered protein drugs market, exceeding US$ 150 Bn by 2025.
What is the expected CAGR value of Bioengineered Protein Drugs Market during the forecast period?
Bioengineered protein drugs market witness a surge at a CAGR of 8.4% during the forecast period (2020-2025).
Bioengineered Protein Drugs Market